A Phase I Trial of A-CAR032 in Participants With mCRPC

Summary

This FTiH, single-arm, open-label, investigator-initiated Phase I trial will evaluate the safety, antitumour activity, CK/pharmacodynamics (PD), biomarkers, immunogenicity, and feasibility of A-CAR032 in adult participants with mCRPC, who have previously progressed after ARPI treatment of prostate cancer (whether before or in the metastatic castration-resistant setting) and, in the judgment of the investigator, are ineligible for standard treatment.

Timeline

Start

2026-01-13

Primary completion

2027-01-31

Completion

2042-01-31

Drugs

Indications